EUVIMEDEUVIMED entdecken
Crossref

Synthesis and Evaluation of 68 Ga- and 177 Lu-Labeled [Pro 14 ]bombesin(8–14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer

Lei Wang, Hsiou-Ting Kuo, Devon E Chapple, Chao-Cheng Chen iD, Sara Kurkowska, Nadine Colpo iD, Carlos Uribe, François Bénard iD, Kuo-Shyan Lin iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Lei Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada. Hauptthemen laut MEDLINE: Receptors, Bombesin, Gallium Radioisotopes, Lutetium, Bombesin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, China Scholarship Council, Alpha-9 Oncology Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gastrin-releasing peptide receptor (GRPR) is overexpressed in a variety of cancers and represents a promising target for diagnosis and therapy. However, the extremely high accumulation in the pancreas observed for most of the clinically evaluated GRPR-targeted radiopharmaceuticals could limit their applications. In this study, we synthesized one GRPR antagonist (ProBOMB5) and two GRPR agonists (LW02056 and LW02057) by replacing the 4-thiazolidinecarboxylic acid (Thz14) residue in our previously reported GRPR-targeted tracers with Pro14. The 68Ga and 177Lu labeling were conducted in HEPES (2 M, pH 5.0) buffer and acetate (0.1 M, pH 4.5) buffer, respectively, and the radiolabeled products were obtained in a 24-57% decay-corrected radiochemical yield and >92% radiochemical purity. The binding affinities (Ki) of Ga-ProBOMB5, Ga-LW02056, Ga-LW02057, and Lu-ProBOMB5 were measured via in vitro competition binding assays and were 12.2 ± 1.89, 14.7 ± 4.81, 13.8 ± 2.24, and 13.6 ± 0.25 nM, respectively. The PET imaging and ex vivo biodistribution studies were conducted in PC-3 tumor-bearing mice at 1 h post injection. [68Ga]Ga-ProBOMB5, [68Ga]Ga-LW02056, and [68Ga]Ga-LW02057 enabled clear tumor visualization in PET images. The tumor uptake values of [68Ga]Ga-ProBOMB5, [68Ga]Ga-LW02056, and [68Ga]Ga-LW02057 were 12.4 ± 1.35, 8.93 ± 1.96, and 7.64 ± 0.55%ID/g, respectively, and their average pancreas uptake values were minimal (0.60-1.37%ID/g). Longitudinal SPECT imaging and ex vivo biodistribution studies were also conducted for [177Lu]Lu-ProBOMB5 and clinically validated [177Lu]Lu-RM2. Despite comparable tumor uptake at 1 h post injection ([177Lu]Lu-ProBOMB5:8.09 ± 1.70%ID/g; [177Lu]Lu-RM2:7.73 ± 0.96%ID/g), a faster clearance from PC-3 tumor xenografts was observed for [177Lu]Lu-ProBOMB5, leading to a lower radiation-absorbed dose delivered to tumors. Our data demonstrate that [68Ga]Ga-ProBOMB5 is a promising tracer for clinical translation for detecting GRPR-expressing tumor lesions. However, further optimizations are needed for [177Lu]Lu-ProBOMB5 to prolong tumor retention for therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, BombesinGallium RadioisotopesLutetiumBombesinRadiopharmaceuticalsRadioisotopesAnimalsMiceHumansTissue DistributionCell Line, TumorMaleMice, NudeProstatic NeoplasmsXenograft Model Antitumor AssaysPancreatic Neoplasms

Stichwörter der Autor:innen

RM2gallium-68gastrin-releasing peptide receptorlutetium-177pancreas uptake

Substanzen

Receptors, BombesinGallium RadioisotopesLutetiumBombesinRadiopharmaceuticalsLutetium-177RadioisotopesGallium-68

Autor:innen und Institutionen

  • Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.
  • Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.
  • Department of Nuclear Medicine, Pomeranian Medical University, Szczecin 70-204, Poland.
  • Department of Molecular Imaging and Therapy, BC Cancer Research Institute, Vancouver, British Columbia V5Z 4E6, Canada.
  • Department of Radiology, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada.

ORCID-Profile: Chao-Cheng Chen, Nadine Colpo, François Bénard, Kuo-Shyan Lin

Förderung

  • Canadian Institutes of Health Research
  • China Scholarship Council
  • Alpha-9 Oncology Inc.

Zitieren

APA

Wang, L., Kuo, H. T., Chapple, D. E., Chen, C. C., Kurkowska, S., Colpo, N., Uribe, C., Bénard, F., & Lin, K. S. (2024). Synthesis and Evaluation of 68 Ga- and 177 Lu-Labeled [Pro 14 ]bombesin(8–14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00952

Vancouver

Wang L, Kuo HT, Chapple DE, Chen CC, Kurkowska S, Colpo N, et al. Synthesis and Evaluation of 68 Ga- and 177 Lu-Labeled [Pro 14 ]bombesin(8–14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00952

BibTeX
@article{Wang2024,
  author = {Wang, Lei and Kuo, Hsiou-Ting and Chapple, Devon E and Chen, Chao-Cheng and Kurkowska, Sara and Colpo, Nadine and Uribe, Carlos and Bénard, François and Lin, Kuo-Shyan},
  title = {Synthesis and Evaluation of 68 Ga- and 177 Lu-Labeled [Pro 14 ]bombesin(8–14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00952}
}
Kostenlos starten →